newsfilter
← Latest News
ACCESS Newswire·

Oncology Pharma, Inc. Has Received the Committed Funding to Perform All Necessary IND-Enabling Preclinical Work for Its First Lead Candidate, a Dactinomycin Nanoemulsion Drug Product

SAN FRANCISCO, CA / ACCESSWIRE / September 13, 2021 / Oncology Pharma, Inc. (OTC:ONPH). In keeping with management's commitment to continue implementation of Oncology Pharma's ("the Company") capital formation plan, the Company has obtained, received and